Durham, North Carolina-based Ribometrix closed on a Series A financing worth $30 million, led by M Ventures.
Swiss pharma giant Novartis announced plans to seek regulatory approval for 60 new treatments between 2019 and 2021.
Indian drugmaker Dr. Reddy’s Laboratories posted a 69.7 percent jump in fiscal second-quarter 2018 profit, helped by new product launches.
To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.
A Simple Checklist and a Little Yellow Box Transform Surgeries from Life-Threatening to Life-Saving Procedures Around the World
International non-profit organization Lifebox, in partnership with healthcare advertising agency precisioneffect, will launch the “Deadliest Conditions” campaign as the American College of Surgeons holds the 2018 Clinical Congress in Boston starting October 21st.
Backed by GlaxoSmithKline and Boston’s SV Health Investors, a new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round.
Johnson & Johnson Vision, a broad-based global leader in eye health, launched a worldwide campaign to #spotlightsight in honor of World Sight Day on October 11, 2018.
The U.S. Food and Drug Administration approved Eli Lilly and Co.’s migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.
Europe approved a fifth copy of AbbVie’s $18-billion-a-year biologic Humira – the world’s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.